Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha?


Sevim H. , Parkinson J. F. , McDonald K. L.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.137, ss.1705-1712, 2011 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 137 Konu: 11
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1007/s00432-011-1046-5
  • Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Sayfa Sayıları: ss.1705-1712

Özet

Treatments which significantly improve progression-free and overall survival for patients with relapsed glioblastoma (GBM) after the standard therapy are lacking. The Topoisomerase II (TopoII) enzyme is a key target of anticancer agents because of the important role it plays in transcription regulation and chromatin remodeling. A drug with strong topoisomerase-mediated anticancer activity is etoposide that is used in combination with carboplatin in patients with relapsed GBM. We hypothesized that tumors harboring high expression of TopoII alpha (TopoIIa) would be more sensitive to etoposide treatment.